What is the standard dosing protocol for Tesamorelin?

Conventional Tesamorelin dosing is 1-2 mg 1x daily subq via subq. For healthspan and biological-age use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What does Tesamorelin stack well with?

For longevity / hallmarks of aging protocols, Tesamorelin pairs with compounds on complementary pathways: Epithalon, Thymalin, NAD+. These pairings are selected because they engage independent receptor systems from Tesamorelin's primary mechanism (Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage), producing additive or synergistic effects rather than receptor competition.

Is Tesamorelin safe during pregnancy or breastfeeding?

Tesamorelin, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ Tesamorelin

Tesamorelin

Longevity

Healthspan-relevant evaluation of Tesamorelin starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat.. The ~30 min pharmacokinetic profile, the cycle-based 1-2 mg 1x daily subq dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.

Longevity / Hallmarks of Aging Applications

Hallmarks of AgingEpigenetic AgingmTOR ModulationInflammagingNutrient Sensing

Key Takeaways

Longevity lens: Tesamorelin maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 1-2 mg 1x daily subq dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

For longevity-relevant evaluation, Tesamorelin's mechanism is examined against the hallmarks of aging rather than against acute clinical endpoints. Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat. The subsections below address the hallmarks mapping, cellular reprogramming layer, healthspan markers, and dosing-pattern conventions in longevity research.

Cellular reprogramming and gene expression

Where Tesamorelin has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Mapping to the hallmarks of aging

Tesamorelin's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Cycle-based versus continuous dosing

Tesamorelin's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Longevity / Hallmarks of Aging Applications

Mitochondrial Biogenesis

Mitochondrial Biogenesis maps to one of the hallmarks of aging and is one of the dimensions on which Tesamorelin is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Cellular Reprogramming

For cellular reprogramming as a longevity-relevant endpoint, Tesamorelin is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Autophagy Induction

Tesamorelin's contribution to autophagy induction as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Hallmarks of Aging

Hallmarks of Aging maps to one of the hallmarks of aging and is one of the dimensions on which Tesamorelin is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-2 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-2 mg	4–6 weeks initial cycle
Longevity focus	SubQ	1-2 mg	1x daily SubQ
Maintenance phase	SubQ	1-2 mg	Ongoing with periodic pauses

Dose timing for Tesamorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

Tesamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

Tesamorelin + Epithalon: Identified by Khavinson in St. Pairs naturally with Tesamorelin's mechanism in longevity / hallmarks of aging protocols.
Tesamorelin + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with Tesamorelin's mechanism in longevity / hallmarks of aging protocols.
Tesamorelin + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with Tesamorelin's mechanism in longevity / hallmarks of aging protocols.
Tesamorelin + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Tesamorelin's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Approved (Egrifta 2010 for HIV lipodystrophy)

Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated.

Lens-specific safety considerations for longevity / hallmarks of aging use of Tesamorelin: Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Tesamorelin for HIV-associated lipodystrophy

PMID 20581419

Supporting

Tesamorelin visceral fat reduction mechanism

PMID 24247738

Tesamorelin vs Related Peptides

Compound	Profile	Onset	Best For
Tesamorelin	Stabilised GHRH analogue	~30 min	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

When in life should I start Tesamorelin?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). Tesamorelin contributes to its specific hallmark layer in this multi-component framework.

Does Tesamorelin actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether Tesamorelin measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

Cycle-based or continuous dosing for longevity?

Longevity-research convention favours cycle-based and pulsatile interventions over indefinite continuous administration. Hormetic stimulation produces stronger systems-biology effects than sustained agonism for most longevity-relevant endpoints. Tesamorelin fits this framework with cycle lengths typical for its compound class.

What is the regulatory status of Tesamorelin?

Tesamorelin regulatory status: Approved (Egrifta 2010 for HIV lipodystrophy) in the United States; WADA status banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does Tesamorelin's half-life affect dosing?

Tesamorelin has a plasma half-life of ~30 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily subq dosing at 1-2 mg per dose explains the typical onset timeline for healthspan and biological-age endpoints.

Clinical Protocol

Start a Tesamorelin Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified Tesamorelin and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 5135 Da
Sequence length: 44 aa
Half-life: ~30 min
WADA: Banned (S2)
FDA: Approved (Egrifta 2010 for HIV lipodystrophy)

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Tesamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for Tesamorelin

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised